SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment towards an immunostimulatory state. Combining sitravatinib with nivolumab (sitra+nivo) may potentially overcome initial CPI resistance. PATIENTS AND METHODS In the phase III SAPPHIRE study, patients with advanced non-oncogenic driven, non-squamous NSCLC who initially benefited from (≥4 months on CPI without progression) and subsequently experienced disease progression on or after CPI combined with or following platinum-based chemotherapy were randomized 1:1 to sitra (100 mg once daily orally)+nivo (240 mg every 2 weeks or 480 mg every 4 weeks intravenous) or docetaxel (75 mg/m2 every 3 weeks intravenous). PRIMARY ENDPOINT overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR; all assessed by blinded independent central review), and safety. RESULTS A total of 577 patients were randomized: sitra+nivo, n = 284; docetaxel, n = 293 (median follow-up, 17.1 months). Sitra+nivo did not significantly improve OS versus docetaxel (median, 12.2 versus 10.6 months; hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.70-1.05; p = 0.144). Median PFS was 4.4 versus 5.4 months, respectively (HR 1.08; 95% CI 0.89-1.32; p = 0.452). ORR was 15.6%, sitra+nivo and 17.2%, docetaxel (p = 0.597); CBR was 75.5% and 64.5%, respectively (p = 0.004); median DOR was 7.4 versus 7.1 months, respectively (p = 0.924). Grade ≥3 treatment-related adverse events were observed in 53.0% versus 66.7% of patients receiving sitra+nivo versus docetaxel, respectively. CONCLUSIONS Although median OS was numerically longer with sitra+nivo, the primary endpoint was not met in patients with previously treated advanced non-squamous NSCLC. The safety profiles demonstrated were consistent with previous reports.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Self-citationde Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Self-citationOvercoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Self-citationNew promises and challenges in the treatment of advanced non-small-cell lung cancer
Meyer, M.-L., Fitzgerald, B. G., Paz-Ares, L., Cappuzzo, F., Jänne, P. A., Peters, S., & Hirsch, F. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01029-8 · Cited by 453
Self-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Metadata
- Authors
- Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W. S. M. E., Percent, I., Gutierrez Calderon, V., Johnson, M. L., Madroszyk-Flandin, A., Garon, E. B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R. S., Leal, T. A., Shazer, R. L., Yan, X., Harrigan, R., Peters, S., Abdel-Karim, I., Abdelsalam, M., Addeo, A., Aguado, C., Alexander, P., Alt, J., Azzi, G., Balaraman, R., Biesma, B., Blackhall, F., Bohnet, S., Boleti, E., Borghaei, H., Bradbury, P., Brighenti, M., Campbell, N., Campbell, T., Canon, J.-L., Cappuzzo, F., Costa, E. C., Cavanna, L., Cetnar, J., Chella, A., Chouaid, C., Christoph, D., Castán, J. C., Dakhil, S., de Castro Carpeño, F. J., de Marinis, F., Delmonte, A., Demedts, I., Demey, W., Dits, J., del Pilar Diz Taín, M., Gómez, M. D., Dorius, T., Dumoulin, D., Duruisseaux, M., Eaton, K., González, E. E., Evans, D., Faehling, M., Farrell, N., Feinstein, T., Font, E. F., Garcia Campelo, M. R., Garon, E., Garrido López, M. P., Germonpré, P., Gersten, T., Cao, M. G., Gopaluni, S., Greillier, L., Grossi, F., Guisier, F., Gurubhagavatula, S., Calderón, V. G., Hakimian, D., Hall, R., Hao, D., Harris, R., Hashemi, S., He, K., Hendriks, L., Huang, C., Ibrahim, E., Jain, S., Johnson, M., Jones, B., Jones, M., Juan Vidal, Ó. J., Juergens, R., Kaderbhai, C., Kastelijn, E. A. (., Keresztes, R., Kio, E., Kokowski, K., Konduri, K., Kulkarni, S., Kuon, J., Kurkjian, C., Labbé, C., Lerner, R., Lim, F., Madroszyk-Flandin, A., Marathe, O., Martincic, D., McClay, E., McIntyre, K., Mekhail, T., Misino, A., Molinier, O., Morabito, A., Morócz, É., Müller, V., Nagy, T., Nguyen, A. V., Nidhiry, E., Okazaki, I., Ortega-Granados, A. L., Ostoros, G., Oubre, D., Owen, S., Pachipala, K., Park, D., Patel, P., Percent, I., Pérol, M., Peters, S., Piet, B., Planchard, D., Polychronis, A., Aix, S. P., Pons-Tostivint, E., Popat, S., Pulla, M. P., Quantin, X., Quéré, G., Rafique, N., Ramaekers, R., Reck, M., Reiman, A., Reinmuth, N., Reynolds, C., Rodríguez-Abreu, D., Romano, G., Roque, T., Salzberg, M., Sanborn, R., Sandiego, S., Schaefer, E., Schreeder, M., Seetharamu, N., Seneviratne, L., Shah, P., Shunyakov, L., Slater, D., Parra, H. S., Stigt, J., Stilwill, J., Su, J., Surmont, V., Swink, A., Szalai, Z., Talbot, T., Garcia, A. T., Theelen, W., Thompson, J., Tiseo, M., Uprety, D., Uyeki, J., van der Leest, K. C., Van Ho, A., van Putten, J., Estévez, S. V., Veatch, A., Vergnenègre, A., Ward, P., Weise, A., Weiss, M., Whitehurst, M., Zai, S., Zalcman, G., & Zuniga, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 35
- Issue
- 1
- Pages
- 66-76
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4387827164
- Cited by
- 103
- References
- 3
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. https://app.cochat.ai/papers/10.1016/j.annonc.2023.10.004
- The paper
- Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W. S. M. E., Percent, I., Gutierrez Calderon, V., Johnson, M. L., Madroszyk-Flandin, A., Garon, E. B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R. S., Leal, T. A., Shazer, R. L., Yan, X., Harrigan, R., . . . Zuniga, R. (2024). SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2023.10.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.